Abstract
Malaria in sub-Saharan Africa (sSA) is thought to be hugely caused by Plasmodium falciparum and very infrequently by P. ovale, P. malariae, with P. vivax not even being considered to be of any significant role. However, with the availability of very sensitive diagnostic tool, it has become more clear that, the percentage of non-falciparum malaria in this sub-region has been underestimated. P. vivax was historically thought to be absent in sSA due to the high prevalence of the Duffy null antigen in individuals residing here. Nevertheless, recent studies reporting the detection of vivax malaria in Duffy-negative individuals challenges this notion. Following our earlier report of P. vivax in Duffy-negative individuals, we have re-assessed all previous samples following the classical PCR method and sequencing to confirm both single/mixed infections as well as the Duffy status of the individuals.
Interestingly, fifteen additional Plasmodium infections were detected, representing 5.9% in prevalence from our earlier work. In addition, P. vivax represents 26.7% (4/15) of the new isolates collected in Nigeria. Sequencing results confirmed, all vivax isolates as truly vivax malaria and their Duffy status to be that of the Duffy-negative genotype. The identification of more vivax isolates among these Duffy-negative individuals from Nigeria, substantiate the expanding body of evidence of the ability of P. vivax to infect RBCs that do not express the DARC gene. Hence, such geno-epidemiological study should be conducted at the national level in order to evaluate the actual burden of P. vivax in the country.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
OMA acknowledges the Department of Science and Technology Government, and Ministry of External Affairs (MEA), Government of India (GoI), and the Federation of Indian Chambers of Commerce and Industry (FICCI), for awarding the Visiting Fellowship under the CV Raman Fellowship scheme.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
All data except the sequence stated in this manuscript are embedded in the manuscript. Sequences would be submitted to the NCBI following manuscript approval.
